| History, applications, and mechanisms of deep brain stimulation S Miocinovic, S Somayajula, S Chitnis, JL Vitek JAMA neurology 70 (2), 163-171, 2013 | 595 | 2013 |
| Automated gait and balance parameters diagnose and correlate with severity in Parkinson disease DC Dewey, S Miocinovic, I Bernstein, P Khemani, RB Dewey III, R Querry, ... Journal of the neurological sciences 345 (1-2), 131-138, 2014 | 98 | 2014 |
| Psychosis in Parkinson disease: a review of etiology, phenomenology, and management N Samudra, N Patel, KB Womack, P Khemani, S Chitnis Drugs & aging 33, 855-863, 2016 | 65 | 2016 |
| Outcomes, management, and potential mechanisms of interleaving deep brain stimulation settings S Miocinovic, P Khemani, R Whiddon, P Zeilman, D Martinez-Ramirez, ... Parkinsonism & related disorders 20 (12), 1434-1437, 2014 | 62 | 2014 |
| Deep brain stimulation and sleep-wake disturbances in Parkinson disease: a review VD Sharma, S Sengupta, S Chitnis, AW Amara Frontiers in neurology 9, 697, 2018 | 42 | 2018 |
| Comparison of globus pallidus interna and subthalamic nucleus in deep brain stimulation for Parkinson disease: an institutional experience and review S Mirza, U Yazdani, R Dewey Iii, N Patel, RB Dewey, S Miocinovic, ... Parkinson’s Disease 2017, 2017 | 37 | 2017 |
| Rivastigmine in Parkinson's disease dementia S Chitnis, J Rao Expert opinion on drug metabolism & toxicology 5 (8), 941-955, 2009 | 37 | 2009 |
| The effect of SPEAK OUT! and The LOUD Crowd on dysarthria due to Parkinson's disease A Behrman, J Cody, S Elandary, P Flom, S Chitnis American Journal of Speech-Language Pathology 29 (3), 1448-1465, 2020 | 36 | 2020 |
| Advanced MRI techniques for transcranial high intensity focused ultrasound targeting BR Shah, VT Lehman, TJ Kaufmann, D Blezek, J Waugh, D Imphean, ... Brain 143 (9), 2664-2672, 2020 | 30 | 2020 |
| Zidovudine (AZT) treatment suppresses granulocyte-monocyte colony stimulating factor receptor type alpha (GM-CSFRα) gene expression in murine bone marrow cells S Chitnis, D Mondal, KC Agrawal Life sciences 71 (8), 967-978, 2002 | 27 | 2002 |
| The effects of the “SPEAK OUT!®” and “LOUD Crowd®” voice programs for Parkinson disease JS Levitt, S Chitnis, D Walker-Batson Int J Health Sci 3 (2), 13-9, 2015 | 26 | 2015 |
| Patient perceptions and knowledge of Parkinson's disease and treatment (KnowPD) MR Salinas, EJ Chambers, T Ho, P Khemani, DWM Olson, S Stutzman, ... Clinical Parkinsonism & Related Disorders 3, 100038, 2020 | 17 | 2020 |
| Gene-expression signatures: biomarkers toward diagnosing multiple sclerosis JT Tossberg, PS Crooke, MA Henderson, S Sriram, D Mrelashvili, ... Genes & Immunity 13 (2), 146-154, 2012 | 14 | 2012 |
| Dysarthria treatment for Parkinson’s disease: one-year follow-up of SPEAK OUT!® with the LOUD Crowd® A Behrman, J Cody, S Chitnis, S Elandary Logopedics Phoniatrics Vocology 47 (4), 271-278, 2022 | 10 | 2022 |
| Cystic lesions as a rare complication of deep brain stimulation VD Sharma, AR Bona, A Mantovani, S Miocinovic, P Khemani, ... Movement disorders clinical practice 3 (1), 87-90, 2016 | 9 | 2016 |
| Optimizing therapeutic effects in patients with comorbidities: drug-resistant tremor, autonomic dysfunction, psychiatric disorders, and cognitive impairment S Chitnis Neurologic clinics 26 (3), 29-44, 2008 | 9 | 2008 |
| Ropinirole treatment for restless legs syndrome S Chitnis Expert Opinion on Drug Metabolism & Toxicology 4 (5), 655-664, 2008 | 8 | 2008 |
| Tetrabenazine in Huntington's disease chorea S Chitnis, CA Karunapuzha Clinical Medicine. Therapeutics 1, CMT. S2134, 2009 | 7 | 2009 |
| Lack of accredited clinical training in movement disorders in Europe, Egypt, and Tunisia G Tamás, M Fabbri, C Falup-Pecurariu, T Teodoro, MM Kurtis, R Aliyev, ... Journal of Parkinson's disease 10 (4), 1833-1843, 2020 | 5 | 2020 |
| Outcomes from switching from rotigotine patch to alternate therapies in Parkinson's disease S Chitnis, M Jaffery, RB Dewey Jr International Journal of Neuroscience 122 (1), 22-25, 2012 | 5 | 2012 |
